ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$17.98 USD
+0.18 (1.01%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $17.97 -0.01 (-0.06%) 6:28 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SPRY 17.98 +0.18(1.01%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Other News for SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ...
ARS Pharmaceuticals Inc (SPRY) Announces Upcoming Conference Call for Q2 2025 Financial Results ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
SPRY Gains Approval for Allergic Reaction Treatment in the UK | SPRY Stock News